ID   P85A_RAT                Reviewed;         724 AA.
AC   Q63787; O55085; P70544; Q63790;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-OCT-2024, entry version 201.
DE   RecName: Full=Phosphatidylinositol 3-kinase regulatory subunit alpha;
DE            Short=PI3-kinase regulatory subunit alpha;
DE            Short=PI3K regulatory subunit alpha;
DE            Short=PtdIns-3-kinase regulatory subunit alpha;
DE   AltName: Full=Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha;
DE            Short=PI3-kinase subunit p85-alpha;
DE            Short=PtdIns-3-kinase regulatory subunit p85-alpha;
GN   Name=Pik3r1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS P85-ALPHA AND P55-ALPHA).
RC   STRAIN=Wistar; TISSUE=Brain;
RX   PubMed=8621382; DOI=10.1074/jbc.271.10.5317;
RA   Inukai K., Anai M., van Breda E., Hosaka T., Katagiri H., Funaki M.,
RA   Fukushima Y., Ogihara T., Yazaki Y., Kikuchi M., Oka Y., Asano T.;
RT   "A novel 55-kDa regulatory subunit for phosphatidylinositol 3-kinase
RT   structurally similar to p55PIK is generated by alternative splicing of the
RT   p85alpha gene.";
RL   J. Biol. Chem. 271:5317-5320(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM P50-ALPHA).
RC   TISSUE=Liver;
RX   PubMed=9065454; DOI=10.1074/jbc.272.12.7873;
RA   Inukai K., Funaki M., Ogihara T., Katagiri H., Kanda A., Anai M.,
RA   Fukushima Y., Hosaka T., Suzuki M., Shin B., Takata K., Yazaki Y.,
RA   Kikuchi M., Oka Y., Asano T.;
RT   "p85alpha gene generates three isoforms of regulatory subunit for
RT   phosphatidylinositol 3-kinase (PI 3-Kinase), p50alpha, p55alpha, and
RT   p85alpha, with different PI 3-kinase activity elevating responses to
RT   insulin.";
RL   J. Biol. Chem. 272:7873-7882(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM P50-ALPHA).
RC   TISSUE=Liver;
RX   PubMed=8921377; DOI=10.1006/geno.1996.0527;
RA   Fruman D.A., Cantley L.C., Carpenter C.L.;
RT   "Structural organization and alternative splicing of the murine
RT   phosphoinositide 3-kinase p85 alpha gene.";
RL   Genomics 37:113-121(1996).
RN   [4]
RP   ACTIVATION BY FGFR4.
RX   PubMed=7518429; DOI=10.1016/s0021-9258(17)32309-8;
RA   Vainikka S., Joukov V., Wennstrom S., Bergman M., Pelicci P.G., Alitalo K.;
RT   "Signal transduction by fibroblast growth factor receptor-4 (FGFR-4).
RT   Comparison with FGFR-1.";
RL   J. Biol. Chem. 269:18320-18326(1994).
RN   [5]
RP   INTERACTION WITH PTK2/FAK1.
RX   PubMed=8824286; DOI=10.1074/jbc.271.42.26329;
RA   Chen H.C., Appeddu P.A., Isoda H., Guan J.L.;
RT   "Phosphorylation of tyrosine 397 in focal adhesion kinase is required for
RT   binding phosphatidylinositol 3-kinase.";
RL   J. Biol. Chem. 271:26329-26334(1996).
RN   [6]
RP   INTERACTION WITH IRS1.
RX   PubMed=8628286; DOI=10.1128/mcb.16.5.2195;
RA   Antonetti D.A., Algenstaedt P., Kahn C.R.;
RT   "Insulin receptor substrate 1 binds two novel splice variants of the
RT   regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain.";
RL   Mol. Cell. Biol. 16:2195-2203(1996).
RN   [7]
RP   ACTIVATION BY FGFR1.
RX   PubMed=11353842; DOI=10.1073/pnas.111114298;
RA   Ong S.H., Hadari Y.R., Gotoh N., Guy G.R., Schlessinger J., Lax I.;
RT   "Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor
RT   receptors is mediated by coordinated recruitment of multiple docking
RT   proteins.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:6074-6079(2001).
CC   -!- FUNCTION: Binds to activated (phosphorylated) protein-Tyr kinases,
CC       through its SH2 domain, and acts as an adapter, mediating the
CC       association of the p110 catalytic unit to the plasma membrane.
CC       Necessary for the insulin-stimulated increase in glucose uptake and
CC       glycogen synthesis in insulin-sensitive tissues. Plays an important
CC       role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF,
CC       KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling.
CC       Modulates the cellular response to ER stress by promoting nuclear
CC       translocation of XBP1 in a ER stress- and/or insulin-dependent manner
CC       during metabolic overloading in the liver and hence plays a role in
CC       glucose tolerance improvement (By similarity).
CC       {ECO:0000250|UniProtKB:P26450, ECO:0000250|UniProtKB:P27986}.
CC   -!- SUBUNIT: Heterodimer of a regulatory subunit PIK3R1 and a p110
CC       catalytic subunit (PIK3CA, PIK3CB or PIK3CD). Interacts (via SH2
CC       domains) with CCDC88A/GIV (tyrosine-phosphorylated form); the
CC       interaction enables recruitment of PIK3R1 to the EGFR receptor,
CC       enhancing PI3K activity and cell migration (By similarity). Interacts
CC       with phosphorylated LAT, LAX1, TRAT1 and LIME1 upon TCR and/or
CC       activation. Interacts with phosphorylated TOM1L1. Interacts with CBLB.
CC       The SH2 domains interact with the YTHM motif of phosphorylated INSR in
CC       vitro. Also interacts with tyrosine-phosphorylated IGF1R in vitro.
CC       Interacts with CD28 and CD3Z upon T-cell activation. Interacts with
CC       NISCH, SOCS7 and HCST. Interacts with RUFY3. Interacts with AXL, FASLG,
CC       FER, FGR, HCK, KIT and BCR. Interacts with PDGFRA (tyrosine
CC       phosphorylated) and PDGFRB (tyrosine phosphorylated). Interacts (via
CC       SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with ERBB4
CC       (phosphorylated). Interacts (via SH2 domain) with TEK/TIE2 (tyrosine
CC       phosphorylated). Interacts with LYN (via SH3 domain); this enhances
CC       enzyme activity. Interacts with NTRK1 (phosphorylated upon ligand-
CC       binding). Interacts with PIK3R2; the interaction is dissociated in an
CC       insulin-dependent manner. Interacts with XBP1; the interaction is
CC       direct and induces translocation of XBP1 into the nucleus in a ER
CC       stress- and/or insulin-dependent but PI3K-independent manner (By
CC       similarity). Interacts with FGFR1, FGFR2, FGFR3 and FGFR4
CC       (phosphorylated) (Probable). Interacts with IRS1 and phosphorylated
CC       IRS4 (PubMed:8628286). Interacts with PTK2/FAK1 (PubMed:8824286).
CC       Interacts with FAM83B; activates the PI3K/AKT signaling cascade (By
CC       similarity). Interacts with APPL1 and APPL2 (By similarity). Interacts
CC       with SRC (By similarity). Interacts with ALOX5; this interaction
CC       bridges ALOX5 with CD40 after CD40 ligation in B cells and leads to the
CC       production of reactive oxygen species (ROS) (By similarity). Interacts
CC       with TYK2 (By similarity). Interacts with nephrin NPHN1; the
CC       interaction is reduced by high glucose levels (By similarity).
CC       Interacts with CD28 (By similarity). {ECO:0000250|UniProtKB:P23727,
CC       ECO:0000250|UniProtKB:P26450, ECO:0000250|UniProtKB:P27986,
CC       ECO:0000269|PubMed:8628286, ECO:0000269|PubMed:8824286, ECO:0000305}.
CC   -!- INTERACTION:
CC       Q63787; P21575: Dnm1; NbExp=2; IntAct=EBI-518443, EBI-80070;
CC       Q63787; P62813: Gabra1; NbExp=4; IntAct=EBI-518443, EBI-6258192;
CC       Q63787; P35570: Irs1; NbExp=2; IntAct=EBI-518443, EBI-520230;
CC       Q63787; Q91V33: Khdrbs1; NbExp=2; IntAct=EBI-518443, EBI-518436;
CC       Q63787; A0MZ67: Shtn1; NbExp=2; IntAct=EBI-518443, EBI-1392040;
CC       Q63787; P18545: PDE6G; Xeno; NbExp=2; IntAct=EBI-518443, EBI-2622029;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=p85-alpha;
CC         IsoId=Q63787-1; Sequence=Displayed;
CC       Name=p55-alpha;
CC         IsoId=Q63787-2; Sequence=VSP_004709, VSP_004710;
CC       Name=p50-alpha;
CC         IsoId=Q63787-3; Sequence=VSP_004711, VSP_004712;
CC   -!- TISSUE SPECIFICITY: The P85-alpha isoform is widely expressed.
CC       Expression of the P55-alpha isoform is highest in brain and skeletal
CC       muscle. The P50-alpha isoform is abundant in liver with lower levels in
CC       brain and muscle.
CC   -!- DOMAIN: The SH3 domain mediates the binding to CBLB. {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated in T-cells by CBLB; which does not promote
CC       proteasomal degradation but impairs association with CD28 and CD3Z upon
CC       T-cell activation. {ECO:0000250}.
CC   -!- PTM: Phosphorylated. Tyrosine phosphorylated in response to signaling
CC       by FGFR1, FGFR2, FGFR3 and FGFR4. Phosphorylated by CSF1R.
CC       Phosphorylated on tyrosine residues by TEK/TIE2. Dephosphorylated by
CC       PTPRJ. Phosphorylated by PIK3CA at Ser-608; phosphorylation is
CC       stimulated by insulin and PDGF. The relevance of phosphorylation by
CC       PIK3CA is however unclear. Phosphorylated in response to KIT and
CC       KITLG/SCF. Phosphorylated by FGR and ERBB4 (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: In adipose tissue, polyubiquitinated by the BCR(KBTBD2) E3
CC       ubiquitin ligase complex; recognized by KBTBD2 through the SH2 domains,
CC       undergoes 'Lys-48'-linked polyubiquitination leading to its
CC       degradation. {ECO:0000250|UniProtKB:P26450}.
CC   -!- SIMILARITY: Belongs to the PI3K p85 subunit family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D64045; BAA18932.1; -; mRNA.
DR   EMBL; D64048; BAA18933.1; -; mRNA.
DR   EMBL; U50412; AAC52846.1; -; mRNA.
DR   EMBL; D78486; BAA24426.1; -; mRNA.
DR   RefSeq; NP_037137.1; NM_013005.1.
DR   PDB; 1FU5; NMR; -; A=322-431.
DR   PDB; 1FU6; NMR; -; A=322-431.
DR   PDBsum; 1FU5; -.
DR   PDBsum; 1FU6; -.
DR   AlphaFoldDB; Q63787; -.
DR   BMRB; Q63787; -.
DR   SMR; Q63787; -.
DR   BioGRID; 247545; 10.
DR   DIP; DIP-33696N; -.
DR   IntAct; Q63787; 18.
DR   MINT; Q63787; -.
DR   STRING; 10116.ENSRNOP00000025687; -.
DR   GlyGen; Q63787; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q63787; -.
DR   PhosphoSitePlus; Q63787; -.
DR   jPOST; Q63787; -.
DR   PaxDb; 10116-ENSRNOP00000025687; -.
DR   GeneID; 25513; -.
DR   KEGG; rno:25513; -.
DR   UCSC; RGD:3329; rat. [Q63787-1]
DR   AGR; RGD:3329; -.
DR   CTD; 5295; -.
DR   RGD; 3329; Pik3r1.
DR   eggNOG; KOG4637; Eukaryota.
DR   InParanoid; Q63787; -.
DR   OrthoDB; 2880119at2759; -.
DR   PhylomeDB; Q63787; -.
DR   Reactome; R-RNO-109704; PI3K Cascade.
DR   Reactome; R-RNO-112399; IRS-mediated signalling.
DR   Reactome; R-RNO-114604; GPVI-mediated activation cascade.
DR   Reactome; R-RNO-1250342; PI3K events in ERBB4 signaling.
DR   Reactome; R-RNO-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-RNO-1266695; Interleukin-7 signaling.
DR   Reactome; R-RNO-1433557; Signaling by SCF-KIT.
DR   Reactome; R-RNO-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-RNO-180292; GAB1 signalosome.
DR   Reactome; R-RNO-186763; Downstream signal transduction.
DR   Reactome; R-RNO-1963642; PI3K events in ERBB2 signaling.
DR   Reactome; R-RNO-198203; PI3K/AKT activation.
DR   Reactome; R-RNO-201556; Signaling by ALK.
DR   Reactome; R-RNO-202424; Downstream TCR signaling.
DR   Reactome; R-RNO-2029485; Role of phospholipids in phagocytosis.
DR   Reactome; R-RNO-210993; Tie2 Signaling.
DR   Reactome; R-RNO-2424491; DAP12 signaling.
DR   Reactome; R-RNO-2730905; Role of LAT2/NTAL/LAB on calcium mobilization.
DR   Reactome; R-RNO-388841; Costimulation by the CD28 family.
DR   Reactome; R-RNO-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-RNO-416476; G alpha (q) signalling events.
DR   Reactome; R-RNO-430116; GP1b-IX-V activation signalling.
DR   Reactome; R-RNO-4420097; VEGFA-VEGFR2 Pathway.
DR   Reactome; R-RNO-512988; Interleukin-3, Interleukin-5 and GM-CSF signaling.
DR   Reactome; R-RNO-5654689; PI-3K cascade:FGFR1.
DR   Reactome; R-RNO-5654695; PI-3K cascade:FGFR2.
DR   Reactome; R-RNO-5654710; PI-3K cascade:FGFR3.
DR   Reactome; R-RNO-5654720; PI-3K cascade:FGFR4.
DR   Reactome; R-RNO-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-RNO-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-RNO-8851907; MET activates PI3K/AKT signaling.
DR   Reactome; R-RNO-8853659; RET signaling.
DR   Reactome; R-RNO-8980692; RHOA GTPase cycle.
DR   Reactome; R-RNO-9009391; Extra-nuclear estrogen signaling.
DR   Reactome; R-RNO-9013026; RHOB GTPase cycle.
DR   Reactome; R-RNO-9013148; CDC42 GTPase cycle.
DR   Reactome; R-RNO-9013149; RAC1 GTPase cycle.
DR   Reactome; R-RNO-9013404; RAC2 GTPase cycle.
DR   Reactome; R-RNO-9013405; RHOD GTPase cycle.
DR   Reactome; R-RNO-9013408; RHOG GTPase cycle.
DR   Reactome; R-RNO-9013409; RHOJ GTPase cycle.
DR   Reactome; R-RNO-9013420; RHOU GTPase cycle.
DR   Reactome; R-RNO-9013424; RHOV GTPase cycle.
DR   Reactome; R-RNO-9027276; Erythropoietin activates Phosphoinositide-3-kinase (PI3K).
DR   Reactome; R-RNO-9035034; RHOF GTPase cycle.
DR   Reactome; R-RNO-912526; Interleukin receptor SHC signaling.
DR   Reactome; R-RNO-912631; Regulation of signaling by CBL.
DR   Reactome; R-RNO-9607240; FLT3 Signaling.
DR   Reactome; R-RNO-9696264; RND3 GTPase cycle.
DR   Reactome; R-RNO-9696270; RND2 GTPase cycle.
DR   Reactome; R-RNO-9696273; RND1 GTPase cycle.
DR   Reactome; R-RNO-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   Reactome; R-RNO-9842663; Signaling by LTK.
DR   EvolutionaryTrace; Q63787; -.
DR   PRO; PR:Q63787; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0005911; C:cell-cell junction; ISO:RGD.
DR   GO; GO:0005801; C:cis-Golgi network; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0016020; C:membrane; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:1990578; C:perinuclear endoplasmic reticulum membrane; ISO:RGD.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:RGD.
DR   GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; IDA:RGD.
DR   GO; GO:0005943; C:phosphatidylinositol 3-kinase complex, class IA; ISS:UniProtKB.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; TAS:RGD.
DR   GO; GO:0046935; F:1-phosphatidylinositol-3-kinase regulator activity; IDA:RGD.
DR   GO; GO:0051117; F:ATPase binding; IPI:RGD.
DR   GO; GO:0005516; F:calmodulin binding; IPI:RGD.
DR   GO; GO:0043125; F:ErbB-3 class receptor binding; ISS:UniProtKB.
DR   GO; GO:0043559; F:insulin binding; ISO:RGD.
DR   GO; GO:0005158; F:insulin receptor binding; ISS:UniProtKB.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IPI:RGD.
DR   GO; GO:0005159; F:insulin-like growth factor receptor binding; ISS:UniProtKB.
DR   GO; GO:0019209; F:kinase activator activity; ISO:RGD.
DR   GO; GO:0005168; F:neurotrophin TRKA receptor binding; ISO:RGD.
DR   GO; GO:0030331; F:nuclear estrogen receptor binding; IPI:RGD.
DR   GO; GO:0035014; F:phosphatidylinositol 3-kinase regulator activity; ISS:UniProtKB.
DR   GO; GO:0036312; F:phosphatidylinositol 3-kinase regulatory subunit binding; ISO:RGD.
DR   GO; GO:0051219; F:phosphoprotein binding; IPI:RGD.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; ISO:RGD.
DR   GO; GO:0005161; F:platelet-derived growth factor receptor binding; IPI:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:RGD.
DR   GO; GO:0046982; F:protein heterodimerization activity; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0019903; F:protein phosphatase binding; ISO:RGD.
DR   GO; GO:0030971; F:receptor tyrosine kinase binding; IPI:RGD.
DR   GO; GO:0005102; F:signaling receptor binding; IPI:RGD.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:RGD.
DR   GO; GO:0030183; P:B cell differentiation; ISO:RGD.
DR   GO; GO:0071398; P:cellular response to fatty acid; IEP:RGD.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEP:RGD.
DR   GO; GO:0034644; P:cellular response to UV; ISO:RGD.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0008625; P:extrinsic apoptotic signaling pathway via death domain receptors; ISO:RGD.
DR   GO; GO:0006006; P:glucose metabolic process; IMP:RGD.
DR   GO; GO:0060396; P:growth hormone receptor signaling pathway; ISO:RGD.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IMP:RGD.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IMP:RGD.
DR   GO; GO:0035655; P:interleukin-18-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0001678; P:intracellular glucose homeostasis; ISS:UniProtKB.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; ISO:RGD.
DR   GO; GO:0097529; P:myeloid leukocyte migration; ISO:RGD.
DR   GO; GO:0042267; P:natural killer cell mediated cytotoxicity; ISO:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0045776; P:negative regulation of blood pressure; IMP:RGD.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; ISO:RGD.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; IMP:RGD.
DR   GO; GO:0001953; P:negative regulation of cell-matrix adhesion; ISO:RGD.
DR   GO; GO:0010459; P:negative regulation of heart rate; IMP:RGD.
DR   GO; GO:0010656; P:negative regulation of muscle cell apoptotic process; IMP:RGD.
DR   GO; GO:0045671; P:negative regulation of osteoclast differentiation; ISO:RGD.
DR   GO; GO:0045861; P:negative regulation of proteolysis; IMP:RGD.
DR   GO; GO:0048662; P:negative regulation of smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0051497; P:negative regulation of stress fiber assembly; ISO:RGD.
DR   GO; GO:0030316; P:osteoclast differentiation; ISO:RGD.
DR   GO; GO:0043491; P:phosphatidylinositol 3-kinase/protein kinase B signal transduction; ISO:RGD.
DR   GO; GO:0046488; P:phosphatidylinositol metabolic process; IDA:RGD.
DR   GO; GO:0046854; P:phosphatidylinositol phosphate biosynthetic process; ISS:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:RGD.
DR   GO; GO:1900103; P:positive regulation of endoplasmic reticulum unfolded protein response; ISS:UniProtKB.
DR   GO; GO:0051491; P:positive regulation of filopodium assembly; ISO:RGD.
DR   GO; GO:0120183; P:positive regulation of focal adhesion disassembly; ISO:RGD.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:RGD.
DR   GO; GO:0010592; P:positive regulation of lamellipodium assembly; ISO:RGD.
DR   GO; GO:0002687; P:positive regulation of leukocyte migration; ISO:RGD.
DR   GO; GO:0045663; P:positive regulation of myoblast differentiation; IMP:RGD.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; ISS:UniProtKB.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; IMP:RGD.
DR   GO; GO:0033120; P:positive regulation of RNA splicing; ISS:UniProtKB.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; ISO:RGD.
DR   GO; GO:0051965; P:positive regulation of synapse assembly; IDA:CACAO.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; ISS:UniProtKB.
DR   GO; GO:0032760; P:positive regulation of tumor necrosis factor production; ISO:RGD.
DR   GO; GO:0006606; P:protein import into nucleus; ISO:RGD.
DR   GO; GO:0050821; P:protein stabilization; ISS:UniProtKB.
DR   GO; GO:1903076; P:regulation of protein localization to plasma membrane; ISO:RGD.
DR   GO; GO:0051492; P:regulation of stress fiber assembly; ISO:RGD.
DR   GO; GO:0034143; P:regulation of toll-like receptor 4 signaling pathway; ISO:RGD.
DR   GO; GO:0043200; P:response to amino acid; IEP:RGD.
DR   GO; GO:0051591; P:response to cAMP; IDA:RGD.
DR   GO; GO:0071548; P:response to dexamethasone; IEP:RGD.
DR   GO; GO:0034976; P:response to endoplasmic reticulum stress; ISS:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0045471; P:response to ethanol; IEP:RGD.
DR   GO; GO:0070542; P:response to fatty acid; IEP:RGD.
DR   GO; GO:0009750; P:response to fructose; IEP:RGD.
DR   GO; GO:0051384; P:response to glucocorticoid; IDA:RGD.
DR   GO; GO:0070848; P:response to growth factor; IEP:RGD.
DR   GO; GO:0032868; P:response to insulin; IDA:RGD.
DR   GO; GO:0010040; P:response to iron(II) ion; IEP:RGD.
DR   GO; GO:0007584; P:response to nutrient; IEP:RGD.
DR   GO; GO:0032570; P:response to progesterone; IEP:RGD.
DR   GO; GO:0033574; P:response to testosterone; IEP:RGD.
DR   GO; GO:0009410; P:response to xenobiotic stimulus; IEP:RGD.
DR   GO; GO:0001878; P:response to yeast; IEP:RGD.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; ISO:RGD.
DR   CDD; cd12924; iSH2_PIK3R1; 1.
DR   CDD; cd04388; RhoGAP_p85; 1.
DR   CDD; cd09930; SH2_cSH2_p85_like; 1.
DR   CDD; cd09942; SH2_nSH2_p85_like; 1.
DR   CDD; cd11910; SH3_PI3K_p85alpha; 1.
DR   Gene3D; 1.10.287.1490; -; 1.
DR   Gene3D; 1.10.555.10; Rho GTPase activation protein; 1.
DR   Gene3D; 3.30.505.10; SH2 domain; 2.
DR   Gene3D; 2.30.30.40; SH3 Domains; 1.
DR   IDEAL; IID50255; -.
DR   InterPro; IPR044124; ISH2_PIK3R1.
DR   InterPro; IPR032498; PI3K_P85_iSH2.
DR   InterPro; IPR035591; PI3K_p85alpha_SH3.
DR   InterPro; IPR035020; PI3kinase_P85_cSH2.
DR   InterPro; IPR035022; PI3kinase_P85_nSH2.
DR   InterPro; IPR008936; Rho_GTPase_activation_prot.
DR   InterPro; IPR000198; RhoGAP_dom.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR036028; SH3-like_dom_sf.
DR   InterPro; IPR001452; SH3_domain.
DR   PANTHER; PTHR10155; PHOSPHATIDYLINOSITOL 3-KINASE REGULATORY SUBUNIT; 1.
DR   PANTHER; PTHR10155:SF10; PI3K21B, ISOFORM B; 1.
DR   Pfam; PF16454; PI3K_P85_iSH2; 1.
DR   Pfam; PF00620; RhoGAP; 1.
DR   Pfam; PF00017; SH2; 2.
DR   PRINTS; PR00678; PI3KINASEP85.
DR   PRINTS; PR00401; SH2DOMAIN.
DR   SMART; SM00324; RhoGAP; 1.
DR   SMART; SM00252; SH2; 2.
DR   SMART; SM00326; SH3; 1.
DR   SUPFAM; SSF48350; GTPase activation domain, GAP; 1.
DR   SUPFAM; SSF55550; SH2 domain; 2.
DR   SUPFAM; SSF50044; SH3-domain; 1.
DR   PROSITE; PS50238; RHOGAP; 1.
DR   PROSITE; PS50001; SH2; 2.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Phosphoprotein;
KW   Protein transport; Reference proteome; Repeat; SH2 domain; SH3 domain;
KW   Stress response; Transport; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000250|UniProtKB:P27986"
FT   CHAIN           2..724
FT                   /note="Phosphatidylinositol 3-kinase regulatory subunit
FT                   alpha"
FT                   /id="PRO_0000080760"
FT   DOMAIN          3..79
FT                   /note="SH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00192"
FT   DOMAIN          113..301
FT                   /note="Rho-GAP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00172"
FT   DOMAIN          333..428
FT                   /note="SH2 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   DOMAIN          624..718
FT                   /note="SH2 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   REGION          80..109
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        84..98
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylserine"
FT                   /evidence="ECO:0000250|UniProtKB:P27986"
FT   MOD_RES         154
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P27986"
FT   MOD_RES         279
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P27986"
FT   MOD_RES         467
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P26450"
FT   MOD_RES         580
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000250|UniProtKB:P27986"
FT   MOD_RES         608
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P23727"
FT   VAR_SEQ         1..300
FT                   /note="Missing (in isoform p50-alpha)"
FT                   /evidence="ECO:0000303|PubMed:8921377,
FT                   ECO:0000303|PubMed:9065454"
FT                   /id="VSP_004711"
FT   VAR_SEQ         1..270
FT                   /note="Missing (in isoform p55-alpha)"
FT                   /evidence="ECO:0000303|PubMed:8621382"
FT                   /id="VSP_004709"
FT   VAR_SEQ         271..304
FT                   /note="VLFRFPAASSDNTEHLIKAVELLISAEWSERQPA -> MYTTVWTMEDLDLE
FT                   CAKTDINCGTDLMFYIEMDP (in isoform p55-alpha)"
FT                   /evidence="ECO:0000303|PubMed:8621382"
FT                   /id="VSP_004710"
FT   VAR_SEQ         301..306
FT                   /note="RQPAPA -> MHNLQT (in isoform p50-alpha)"
FT                   /evidence="ECO:0000303|PubMed:8921377,
FT                   ECO:0000303|PubMed:9065454"
FT                   /id="VSP_004712"
FT   STRAND          324..327
FT                   /evidence="ECO:0007829|PDB:1FU5"
FT   HELIX           340..346
FT                   /evidence="ECO:0007829|PDB:1FU5"
FT   STRAND          347..349
FT                   /evidence="ECO:0007829|PDB:1FU5"
FT   STRAND          358..360
FT                   /evidence="ECO:0007829|PDB:1FU6"
FT   STRAND          363..365
FT                   /evidence="ECO:0007829|PDB:1FU6"
FT   STRAND          371..374
FT                   /evidence="ECO:0007829|PDB:1FU6"
FT   STRAND          377..380
FT                   /evidence="ECO:0007829|PDB:1FU6"
FT   STRAND          385..393
FT                   /evidence="ECO:0007829|PDB:1FU5"
FT   HELIX           403..407
FT                   /evidence="ECO:0007829|PDB:1FU5"
FT   STRAND          408..411
FT                   /evidence="ECO:0007829|PDB:1FU5"
FT   STRAND          415..417
FT                   /evidence="ECO:0007829|PDB:1FU5"
SQ   SEQUENCE   724 AA;  83531 MW;  95C65CF612873B84 CRC64;
     MSAEGYQYRA LYDYKKEREE DIDLHLGDIL TVNKGSLVAL GFSDGQEARP EDIGWLNGYN
     ETTGERGDFP GTYVEYIGRK RISPPTPKPR PPRPLPVAPG SSKTEADTEQ PVLTLPDLAE
     QFAPPDVAPP LLIKLLEAIE KKGLECSTLY RTQSSSNPAE LRQLLDCDPP SVDLDVFDEH
     VLADAFKRYL ADLPNPVIPV AVYNEMMSLA QEVPSSEDYI QLLKKLIRSP NIPHQYWLTL
     QYLLKHFFKL SQASSKNLLN ARALSEIFSH VLFRFPAASS DNTEHLIKAV ELLISAEWSE
     RQPAPALPPK PPKPTSIANN SMNNNMSLQD AEWYWGDISR EEVNEKLRDT ADGTFLVRDA
     STKMHGDYTL TLRKGGNNKL IKIFHRDGKY GFSDPLTFNS VVELINHYRN ESLAQYNPKL
     DVKLLYPVSK YQQDQVVKED NIEAVGKKLH EYNTQFQEKS REYDRLYEEY TRTSQEIQMK
     RTAIEAFNDT IKIFEEQCHP QERYSKDYIE KFKREGNEKE IQRIMHNHDK LKSRISEIID
     SRRRLEEDLK KQAAEYREID KRMNSIKPDL IQLRKTRDQY LMWLTQKGVR QKKLNEWLGN
     ENTEDQYSLV DDDEDLPHHD EKTWNVGSSN RNKAENLLRG KRDGTFLVRE SSKQGCYACS
     VVVDGEVKHC VINKTATGYG FAEPYNLYSS LKELVLHYQH TSLVQHNDSL NVTLAYPVYA
     QQRR
//
